Inclusion Criteria:
  1. Initiation of treatment with a single ICI or a combination of ICIs.
  2. Acceptation of an informed consent.
Exclusion Criteria:
  1. Life expectancy lower than 3 months from the initiation of treatment with ICIs.
  2. Proven hypersensitivity or previous allergic anaphylactic reaction induced by a specific ICI.
  3. Active autoimmune disease with severe involvement.
  4. Eastern Cooperative Oncology Group (ECOG) performance status â‰¥ 3.
  5. Ongoing immunosuppressive therapy: prednisone at doses >10 mg/day or equivalent (>1.5 mg/day of dexamethasone), and/or any dose of azathioprine, methotrexate, mycophenolate, cyclophosphamide, leflunomide, rituximab, anti-tumor necrosis factor drugs (infliximab, etanercept, adalimumab, golimumab), belimumab and abatacept.